⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Form 8-K
sec.gov
AGEN
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
businesswire.com
AGEN
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
businesswire.com
AGEN
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
businesswire.com
AGEN
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
businesswire.com
GSK
AGEN
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
businesswire.com
GSK
AGEN
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
businesswire.com
AGEN
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
businesswire.com
AGEN
Agenus to Host First 2026 Stakeholder Webcast
businesswire.com
AGEN
Agendia gibt Aktualisierung der NCCN-Richtlinien bekannt, in denen MammaPrint als Leitfaden für den personalisierten Einsatz von Anthrazyklinen bei HR+/HER2- Brustkrebs im Frühstadium anerkannt wird
businesswire.com
AGEN